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Abstract
Background: LIM-only 4 (LMO4), a member of the LIM-only (LMO) subfamily of LIM domain-
containing transcription factors, was initially reported to have an oncogenic role in breast cancer.
We hypothesized that LMO4 may be related to pancreatic carcinogenesis as it is in breast
carcinogenesis. If so, this could result in a better understanding of tumorigenesis in pancreatic
cancer.
Methods:  We measured LMO4  mRNA levels in cultured cells, pancreatic bulk tissues and
microdissected target cells (normal ductal cells; pancreatic intraepithelial neoplasia-1B [PanIN-1B]
cells; PanIN-2 cells; invasive ductal carcinoma [IDC] cells; intraductal papillary-mucinous adenoma
[IPMA] cells; IPM borderline [IPMB] cells; and invasive and non-invasive IPM carcinoma [IPMC]) by
quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR).
Results: 9 of 14 pancreatic cancer cell lines expressed higher levels of LMO4 mRNA than did the
human pancreatic ductal epithelial cell line (HPDE). In bulk tissue samples, expression of LMO4 was
higher in pancreatic carcinoma than in intraductal papillary-mucinous neoplasm (IPMN) or non-
neoplastic pancreas (p < 0.0001 for both). We carried out microdissection-based analyses. IDC
cells expressed significantly higher levels of LMO4 than did normal ductal epithelia or PanIN-1B cells
(p < 0.001 for both) or PanIN-2 cells (p = 0.014). IPMC cells expressed significantly higher levels of
LMO4 than did normal ductal epithelia (p < 0.001), IPMA (p < 0.001) and IPMB cells (p = 0.003).
Conclusion: Pancreatic carcinomas (both IDC and IPMC) expressed significantly higher levels of
LMO4 mRNA than did normal ductal epithelia, PanIN-1B, PanIN-2, IPMA and IPMB. These results
suggested that LMO4 is overexpressed at late stages in carcinogenesis of pancreatic cancer.
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Introduction
Pancreatic cancer is one of the most aggressive malignant
tumors. It is the fifth leading cause of cancer death in
Japan [1,2] and has the lowest survival rate of any solid
cancer [3]. Because the lack of specific symptoms in
patients with pancreatic cancer makes early diagnosis dif-
ficult, initial diagnosis typically occurs when the tumor
has reached an advanced stage [4]. A better understanding
of pancreatic carcinogenesis is urgently needed to facili-
tate early detection. Pancreatic intraepithelial neoplasia
(PanIN) and intraductal papillary-mucinous neoplasm
(IPMN) were reported to be precursor lesions of pancre-
atic cancer [5-8]. Development of invasive ductal adeno-
carcinoma has been proposed to occur via two pathways
[9-11], the PanIN-Invasive ductal carcinoma (IDC) pro-
gression pathway and the IPM adenoma (IPMA)-invasive
IPM carcinoma (IPMC) pathway, although some specific
subtypes of IPMN, such as intestinal-type IPMN, may not
progress to invasive carcinoma through the same genetic
pathway as PanIN. Longnecker et al [12] reported that
PanIN-1 and IPMA showed mild dysplasia (grade 1),
PanIN-2 and IPM borderline (IPMB) lesions showed
moderate dysplasia (grade 2), and PanIN-3 and IPMC
(carcinoma in situ [CIS]) showed severe dysplasia (grade
3).
LIM-only 4 (LMO4) is one of the four members (LMOs 1,
2, 3 and 4) of the LIM-only subfamily of LIM domain pro-
teins. LIM domains are an approximately 55-amino acid,
cysteine-rich, zinc-binding motif that mediate protein-
protein interactions present in a variety of proteins includ-
ing LIM homeobox proteins [13]. The nuclear LIM-only
proteins (LMOs 1–4) lack a DNA-binding domain but
still function as transcriptional regulators by recruiting
other protein partners including transcription factors
[14,15]. Kenny et al [13] reported the isolation and char-
acterization of LMO4, a novel LIM-only gene that is highly
expressed in the T-lymphocyte lineage, cranial neural crest
cells, somites, dorsal limb bud mesenchyme, motor neu-
rons and Schwann cell progenitors. As well as its role in
development, there are several lines of evidence suggest-
ing that LMO4 may have roles in oncogenesis [16].
LMO4, initially described as a human breast tumor
autoantigen [17], was reported to have a role in maintain-
ing proliferation of mammary epithelium and suggested
that deregulation of this gene may contribute to breast
tumorigenesis [18]. Additionally, Sum et al [19] found
that LMO4 interacts with the cofactor CtIP and the tumor
suppressor breast cancer 1 (BRCA1), and inhibits the tran-
scriptional activity of BRCA1 in both yeast and mamma-
lian cells by functional assays. They concluded that
deregulation of LMO4 in breast epithelium directly con-
tributes to breast neoplasia by altering the rate of cellular
proliferation and promoting cell invasion. In 2005, Sum
and colleagues reported that LMO4 mRNA was overex-
pressed in 5 of 10 human breast cancer cell lines; in situ
hybridization analysis of 177 primary invasive breast car-
cinomas revealed overexpression of LMO4 in 56% of the
specimens [20]. It has also been reported that expression
of LMO4 is up-regulated at the invasive front of oral can-
cer, suggesting a role in cancer cell invasion [21]. It was
recently reported that the bone morphogenic protein
(BMP7) gene, which controls cell proliferation and apop-
tosis of mammary epithelial cells, is a direct target of
LMO4 [22]. Both pancreatic cancer and breast cancer are
known to have an epithelial origin while pancreatic can-
cer also reveals papillo-tubular structures that are similar
to the histological characteristics of the initial breast can-
cer [23]. As well, known genetic changes in pancreatic can-
cer often involve the same genes as those found in breast
cancer [24]. Taken together, these findings suggest that
LMO4 has critical functions in pancreatic carcinogenesis
as well as in normal development. Thus clarification of
the role of LMO4 may be useful for diagnosis and/or treat-
ment of pancreatic cancer. However, little is known about
the role of LMO4 in pancreatic cancer and carcinogenesis.
To determine whether LMO4 is correlated with pancreatic
cancer and carcinogenesis, we quantified LMO4 mRNA
levels in cultured pancreatic cell lines, bulk tissues and
microdissection-based target cells (including normal pan-
creatic ductal, PanIN-1B and PanIN-2, IDC, IPMA, IPMB
and IPMC cells), by quantitative real-time reverse tran-
scription-polymerase chain reaction (qRT-PCR). Our goal
was to characterize LMO4 expression in the early and late
stages of pancreatic carcinogenesis to clarify both if and
when overexpression of LMO4 occurs.
Materials and methods
Cultured cells
Fourteen pancreatic cancer cell lines, AsPC-1, KP-1N, KP-
2, KP-3, PANC-1, SUIT-2 (provided by Dr. H. Iguchi,
National Shikoku Cancer Center, Matsuyama, Japan),
MIA PaCa-2 (Japanese Cancer Resource Bank, Tokyo,
Japan), NOR-P1 (established in our laboratory), CAPAN-
1, CAPAN-2, CFPAC-1, H48N, HS766T and SW1990
(American Type Culture Collection, Manassas, VA, USA),
the HPDE cell line and six primary cultures of fibroblasts
derived from pancreatic tumors were studied. Cells were
maintained as described previously [25].
Pancreatic tissues
Tissue samples were obtained during surgery at Kyushu
University Hospital (Fukuoka, Japan) as described previ-
ously [26]. In brief, tissue samples were removed and
divided into at least three bulk tissue specimens. The first
sample was immediately but temporarily preserved in
cold PBS and then embedded in OCT compound (Sakura
Findek, Tokyo, Japan), snap-frozen for microdissection
within 1 hour after resection, and stored at -80°C untilMolecular Cancer 2008, 7:93 http://www.molecular-cancer.com/content/7/1/93
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use. The second sample was fixed in formalin, embedded
in paraffin and cut into 4-μm-thick sections for hematox-
ylin and eosin (H&E) staining. The third sample was
immediately snap-frozen for bulk tissue analysis and
stored at -80°C until use. Tissues adjacent to the speci-
mens were examined histologically and the diagnosis con-
firmed by two pathologists, Dr Hiroshi Yamaguchi and Dr
Kohei Nakata (Figure 1). Written informed consent was
obtained from all patients, and the study was approved by
our institution's surveillance committee and conducted
according to the Helsinki Declaration.
RNA isolation
Total RNA was extracted from cultured cells with a High
Pure RNA Isolation Kit (Roche, Mannheim, Germany).
Total RNA was extracted from bulk tissues with an RNeasy
Mini Kit (Qiagen, Tokyo, Japan) following the manufac-
turer's protocol. Total RNA was extracted from cells iso-
lated by microdissection with the standard acid
guanidinium thiocyanate-phenol-chloroform protocol
[27] with or without glycogen (Funakoshi, Tokyo, Japan)
[26].
Quantitative assessment of LMO4 level by real-time RT-
PCR
Quantitative real-time RT-PCR was performed with a
QuantiTect SYBR Green RT-PCR Kit (Qiagen, Tokyo,
Japan) with a Chromo4™ System (Bio-Rad, Hercules, CA,
USA). In brief, the reaction mixture was first incubated at
50°C for 30 min to allow for reverse transcription. PCR
was initiated with one cycle of 95°C for 15 min to activate
the modified Taq polymerase followed by 40 cycles of
94°C for 15 sec, 55°C for 20 sec, and 72°C for 10 sec, and
one cycle of 95°C for 0 sec, 65°C for 15 sec and +0.1°C/
sec to 95°C for melting analysis. Each sample was run in
triplicate. The level of LMO4 mRNA expression was calcu-
lated from a standard curve constructed with total RNA
from the SUIT-2 pancreatic cancer cell line. The range of
threshold cycles was from 20–35 cycles for LMO4 primers
(forward, 5'-GGA CCG CTT TCT GCT CTA TG-3'; reverse,
5'-AAG GAT CAT GCC ACT TTT GG-3'), and from 7–35
cycles for 18S rRNA primers (forward 5'-GAT ATG CTC
ATG TGG TGT TG-3'; reverse, 5'-AAT CTT CTT CAG TCG
CTC CA-3'). Expressions of LMO4 mRNA were normal-
ized to that of 18S rRNA.
Histologic examination of formalin-fixed, paraffin-embedded (FFPE) samples with hematoxylin and eosin (H&E) staining Figure 1
Histologic examination of formalin-fixed, paraffin-embedded (FFPE) samples with hematoxylin and eosin 
(H&E) staining. The stages of the PanIN-IDC pathway are shown as normal pancreatic ductal epithelia (A), pancreatic 
intraepithelial neoplasm-1B (PanIN-1B) (B), PanIN-2 (C) and invasive ductal carcinoma (IDC) (D). The stages of the intraductal 
papillary mucinous adenoma (IPMA)-intraductal papillary mucinous carcinoma (IPMC) pathway are shown as IPM adenoma (E), 
IPM borderline (F) and IPM carcinoma (G). (Magnifications of A to G are 100×, 100×, 100×, 200×, 100×, 200×, 200×, respec-
tively).Molecular Cancer 2008, 7:93 http://www.molecular-cancer.com/content/7/1/93
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Microdissection-based quantitative analysis of LMO4 
mRNA
Frozen tissues were cut into 8-μm-thick sections. IDC cells
from 8 lesions, PanIN-2 cells from 3 lesions, PanIN-1B
cells from 14 lesions, normal ductal epithelial cells from
13 ducts, IPMA cells from 13 lesions, IPMB cells from 15
lesions, and IPMC cells from 8 lesions, including 3 non-
invasive IPMC lesions (CIS) and 5 invasive IPMC lesions,
were selectively isolated with a laser microdissection and
pressure catapulting system (P.A.L.M. Microlaser Technol-
ogies, Bernried, Germany) in accordance with the manu-
facturer's protocols (Figure 2) [28]. After microdissection,
Pictures of pancreatic normal ductal epithelia, PanIN-1B, IDC, IPMA, IPMB and IPMC lesions stained with 1% toluidine blue Figure 2
Pictures of pancreatic normal ductal epithelia, PanIN-1B, IDC, IPMA, IPMB and IPMC lesions stained with 1% 
toluidine blue. Lanes 1 to 4 show the process of microdissecting the target cells. Before cutting (lane 1), after cutting (lane 2), 
rest of region (lane 3) and target cells in capture (lane 4). (The magnifications are shown on the pictures).Molecular Cancer 2008, 7:93 http://www.molecular-cancer.com/content/7/1/93
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total RNA was extracted from the selected cells and sub-
jected to qRT-PCR for quantitative measurement of LMO4
as described previously [26].
Statistical analysis
Data were analyzed with multiple comparison in ANOVA
(analysis of variance) and Bivariate Correlations with Sta-
tistics Package for Social Science (SPSS) software (SPSS
Inc. Chicago, IL, USA) after Kolmogorov-Smirnov test to
assure that each data set is showed a normal distribution.
For multiple comparisons by ANOVA, we used the least
significant difference (LSD) test and set the statistical sig-
nificance at p < 0.05. We used Spearman test for bivariate
correlations.
Results
Quantitative analysis of LMO4 expression in 14 
pancreatic cancer cell lines, a non-neoplastic ductal 
epithelial cell line and six primary cultures of pancreatic 
fibroblasts
We investigated LMO4 mRNA expression in 14 pancreatic
cancer cell lines, HPDE, a normal pancreatic ductal cell
line immortalized by transduction with the E6/E7 genes
of human papillomavirus 16 [29,30], and 6 primary cul-
tures of pancreatic fibroblasts derived from resected pan-
creatic tumors. As shown in Figure 3, 9 of the 14
pancreatic cancer cell lines expressed higher levels of
LMO4 than did HPDE. We also found that all 6 primary
cultures of pancreatic fibroblasts expressed moderate lev-
els of LMO4. Four pancreatic cancer cell lines, Hs766T,
AsPC-1, KP-2 and KP-3, expressed higher levels of LMO4
than did any of the primary cultures of pancreatic fibrob-
lasts. We next examined whether LMO4  expression is
related to the origin of these cancer cell lines, but found
no correlation between LMO4 expression and site of ori-
gin, such as primary or metastatic tumors (Figure 3).
Quantitative analyses of LMO4 expression in bulk 
pancreatic tissues
In the bulk tissue analyses, we measured LMO4 expres-
sion in pancreatic cancer tissues (n = 11), and non-neo-
plastic tissues (n  = 20), normal pancreatic or chronic
pancreatitis-related tissues, and non-malignant IPMN tis-
sues (n = 11). As shown in Figure 4, LMO4 expression was
highest in the pancreatic cancer tissues with a mean of
0.24 (95% confidence interval [CI], 0.16 – 0.32), whereas
the LMO4 expression levels were 0.03 (95% CI, 0.02 –
0.04) in non-neoplastic tissues and 0.08 (95% CI, 0.04 –
0.12) in non-malignant IPMN tissues. The mean LMO4
mRNA level in pancreatic cancer tissues was eight-fold
higher than that in non-neoplastic tissues (p < 0.0001)
and three-fold higher than that in non-malignant IPMN
tissues (p < 0.0001). The mean LMO4 mRNA level in non-
malignant IPMN tissues was 2.7-fold higher than that in
non-neoplastic tissues, although the difference was not
statistically significant (p = 0.053). All data from bulk tis-
sue analyses indicated that LMO4 was overexpressed in
pancreatic cancer.
Microdissection-based quantitative analysis of LMO4 
expression in IDC, PanIN-2, PanIN-1B and normal ductal 
cells
In general, bulk pancreatic tissues are composed of a vari-
ous types of cells, including ductal epithelial, acinar, islet
and mesenchymal cells, and fibroblasts. Cancer cells com-
prise only 30% – 70% of the cells in bulk tissue specimens
of pancreatic cancer [27]. Premalignant cells, such as
PanINs, and normal ductal cells comprise even smaller
percentages of the cells in non-malignant tissues. The
results of our present analyses of cultured cells suggested
that LMO4 was expressed in pancreatic fibroblasts (Figure
3). Therefore, to avoid the influence of contaminating
non-ductal cells, we used a laser-microdissection (LMD)
method to select specific ductal cells for further analysis.
LMO4 expressions in pancreatic cancer cell lines, a human  pancreatic ductal epithelial (HPDE) cell line and primary  fibroblasts derived from pancreatic tumors Figure 3
LMO4 expressions in pancreatic cancer cell lines, a 
human pancreatic ductal epithelial (HPDE) cell line 
and primary fibroblasts derived from pancreatic 
tumors. Hs766T, AsPC-1, SUIT-2, CAPAN-1, KP-3, KP-2, 
CAPAN-2, PANC-1 and MIA PaCa-2 cells expressed signifi-
cantly higher levels of LMO4 (median, 1.07) than did the 
HPDE cells (median, 0.46). All 6 cultures of primary fibrob-
lasts express moderate levels of LMO4 (median, 0.70). The 
difference in LMO4 expression between the metastasis group 
(Hs766T, AsPC-1, SW1990, NOR-P1, SUIT-2 and CAPAN-1; 
median = 1.06) and the non-metastasis group (KP-2, KP-3, 
CAPAN-2, PANC-1, MIA PaCa-2 and H48N; median = 0.76) 
is not statistically significant (p = 0.75). Expression of LMO4 
mRNA was normalized to that of 18S rRNA.Molecular Cancer 2008, 7:93 http://www.molecular-cancer.com/content/7/1/93
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To investigate the involvement of LMO4 in the PanIN-
IDC pathway, we isolated IDC cells from 8 lesions, PanIN-
2 cells from 3 lesions, PanIN-1B cells from 14 lesions and
normal ductal epithelial cells from 13 ducts by LMD (Fig-
ure 2) for quantitative analysis of LMO4 by RT-PCR. As
shown in Figure 5, IDC cells expressed significantly higher
levels of LMO4  than did normal ductal epithelial or
PanIN-1B cells (p < 0.0001 for both) or PanIN-2 cells (p =
0.014). The mean LMO4 expression level was 2.19 (95%
CI, 1.43 – 2.94) in IDC cells, 0.32 (95% CI, 0.18 – 0.45)
in PanIN-2 cells, 0.41 (95% CI, 0.27 – 0.54) in PanIN-1B
cells and 0.45 (95% CI, 0.30 – 0.60) in normal ductal epi-
thelial cells. The difference in LMO4 expression between
PanIN-2 and normal ductal cells or between PanIN-1B
and normal ductal cells was not significant (p = 0.54 and
p = 0.56, respectively). These data suggested that LMO4 is
overexpressed in pancreatic cancer, especially in the inva-
sive step of cancer, but not in the early stage of pancreatic
carcinogenesis.
Quantitative analyses of LMO4 expressions in IPMC, 
IPMB, IPMA and normal ductal cells
To investigate the correlation of LMO4 expression with
the IPMA-IPMC pathway, we microdissected IPMC cells
from 5 invasive lesions and 3 non-invasive lesions (CIS),
IPMB cells from 15 lesions, IPMA cells from 13 lesions
and normal ductal epithelial cells from 6 ducts. We then
measured  LMO4  expression in these cells by qRT-PCR
(Figure 2). As shown in Figure 6, IPMC cells expressed
higher levels of LMO4 (mean, 1.79; 95% CI, 0.99 – 2.58),
than did normal ductal cells (p < 0.001), IPMA cells (p <
0.001) and IPMB cells (p = 0.003). There was no signifi-
LMO4 expressions in bulk pancreatic tissues, including 20  non-neoplastic tissues, 11 non-malignant IPMN tissues and 11  pancreatic cancer tissues Figure 4
LMO4 expressions in bulk pancreatic tissues, includ-
ing 20 non-neoplastic tissues, 11 non-malignant 
IPMN tissues and 11 pancreatic cancer tissues. The 
mean LMO4 expression value for pancreatic cancer samples 
is 0.24 (95% CI; 0.16 – 0.32), which is higher than the LMO4 
level of non-malignant IPMN (mean, 0.08; 95% CI, 0.04 – 
0.12) or non-neoplastic tissues (mean, 0.03; 95% CI, 0.02 – 
0.04). The difference in LMO4 expression between non-
malignant IPMN and non-neoplastic tissues is not statistically 
significant (p = 0.053). The bottom and the top edges of the 
box mark the lower bound and upper bound of the 95% 
Confidence Interval for the Mean, respectively. The center 
horizontal line is drawn at the sample mean. The center ver-
tical lines drawn from the boxes extend to the minimum and 
the maximum. Expression of LMO4 mRNA was normalized 
to that of 18S rRNA.
LMO4 expressions in the PanIN-IDC pathway, including 13  normal ductal epithelial ducts, 14 PanIN-1B lesions, 3 PanIN- 2 lesions, and 8 IDC lesions Figure 5
LMO4 expressions in the PanIN-IDC pathway, includ-
ing 13 normal ductal epithelial ducts, 14 PanIN-1B 
lesions, 3 PanIN-2 lesions, and 8 IDC lesions. IDC cells 
(mean, 2.19; 95% CI, 1.43 – 2.94) expressed significantly 
higher levels of LMO4 than did normal ductal epithelia (mean, 
0.45; 95% CI, 0.30 – 0.60), PanIN-1B (mean, 0.41; 95% CI, 
0.27 – 0.54), or PanIN-2 cells (mean, 0.32; 95%CI 0.18 – 
0.45). The differences in LMO4 expression among PanIN-2, 
PanIN-1B, and normal ductal epithelial cells are not statisti-
cally significant (p = 0.54 and p = 0.56). The bottom and the 
top edges of the box mark the lower bound and upper 
bound of the 95% Confidence Interval for the Mean, respec-
tively. The center horizontal line is drawn at the sample 
mean. The center vertical lines drawn from the boxes extend 
to the minimum and the maximum. Expression of LMO4 
mRNA was normalized to that of 18S rRNA.Molecular Cancer 2008, 7:93 http://www.molecular-cancer.com/content/7/1/93
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cant difference in LMO4  expression between invasive
IPMC and non-invasive IPMC (CIS). Although the mean
LMO4 expression in IPMB cells (0.98; 95% CI, 0.69 –
1.27) was higher than that in IPMA (0.60; 95% CI, 0.47 –
0.73) or normal ductal cells (0.65; 95% CI, 0.34 – 0.95),
the differences in LMO4 expression were not significant.
Taken together, these data suggested that LMO4 expres-
sion may be up-regulated during the late stages of carcino-
genesis of IPMN.
Quantitative analyses of LKB1 expressions in cultured and 
microdissected cells, and correlation analyses between 
LKB1 and LMO4 in pancreatic carcinogenesis
LKB1 (also called STK11) is a tumor suppressor gene in
Peutz-Jeghers syndrome [31]. Loss of this gene is found in
pancreatic cancer [32,33]. Recently, LKB1 was reported to
induce p21 expression in collaboration with LMO4 [34].
To investigate the potential role of LMO4 in pancreatic
carcinogenesis, we measured LKB1 mRNA expression in
cultured and microdissected cells and investigated any
correlation between LKB1 and LMO4 expression. In the
analysis of cultured cells, we found significant correlation
between LKB1 and LMO4 mRNA levels in primary cul-
tured fibroblasts (n = 6, spearman test, p = 0.024; Figure
7a, top). By contrast, there was no significant correlation
between LKB1 and LMO4 mRNA levels in cultured cancer
cell lines (n = 14, spearman test, p = 0.33; Figure 7a bot-
tom). In the analysis of microdissected cells, IDC cells
expressed significantly lower levels of LKB1 mRNA than
did PanIN-1B or normal ductal cells (n = 12, p = 0.02; n =
8; p = 0.002, respectively; Figure 7b top). There was a sig-
nificant correlation between LKB1 and LMO4 mRNA lev-
els in non-malignant cells, including normal pancreatic
ductal epithelia and PanIN-1B cells (n = 20, p = 0.042, Fig-
ure 7b middle), but no significant correlation in IDC cells
(n = 8, p = 0.45, Figure 7b bottom).
Discussion
In the present study, we performed quantitative real-time
RT-PCR to measure LMO4 expression during pancreatic
carcinogenesis through the PanIN-IDC and IPMA-IPMC
pathways. Analyses of cultured cells revealed that 9 of 14
pancreatic cancer cell lines and all primary cultures of
pancreatic fibroblasts expressed higher levels of LMO4
than did a non-neoplastic pancreatic ductal cell line. Bulk
tissue analysis showed that pancreatic cancer tissues
expressed higher levels of LMO4 than non-neoplastic and
non-malignant IPMN tissues; however, the difference in
LMO4  expression between non-neoplastic tissues and
non-malignant IPMN was not significant. To avoid the
influence of LMO4-expressing non-ductal cells contained
in bulk tissues, we microdissected target cells, such as
IDCs, PanINs, IPMNs and non-neoplastic ductal cells, and
measured LMO4 expression in the microdissected cells. It
is usually difficult to obtain frozen sections of intermedi-
ate or high-grade PanIN-2 or PanIN-3 (CIS) or non-inva-
sive IPMC (CIS) lesions. In the present study, we obtained
frozen sections from 3 cases of PanIN-2 lesions and 3 of
non-invasive IPMC. We found that the LMO4 expression
in IDC cells was significantly higher than those in PanIN-
1B, PanIN-2, and normal ductal cells; however, the
PanIN-2 sample number was small. We also found that
both invasive and non-invasive IPMC cells expressed
LMO4 expressions in the IPMA-IPMC pathway, including 6  normal ductal epithelial ducts, 13 IPMA lesions, 15 IPMB  lesions and 8 IPMC lesions (5 for invasive IPMC and 5 for  non-invasive IPMCs) Figure 6
LMO4 expressions in the IPMA-IPMC pathway, 
including 6 normal ductal epithelial ducts, 13 IPMA 
lesions, 15 IPMB lesions and 8 IPMC lesions (5 for 
invasive IPMC and 5 for non-invasive IPMCs). IPMC 
cells expressed significantly higher levels of LMO4 (mean, 
1.79; 95% CI, 0.99 – 2.58) than did IPMB (mean, 0.98; 95% CI, 
0.69 – 1.27) (p = 0.003), IPMA (mean, 0.60; 95% CI, 0.47 – 
0.73) (p < 0.001), or normal ductal epithelial cells (mean, 
0.65; 95% CI, 0.34 – 0.95) (p < 0.001). The differences in 
LMO4 expression between IPMB and IPMA cells (p = 0.09), 
IPMB and normal ductal epithelial cells (p = 0.2) and IPMA 
and normal ductal epithelial cells (p = 0.9) are not significant. 
The bottom and the top edges of the box mark the lower 
bound and upper bound of the 95% Confidence Interval for 
the Mean, respectively. The center horizontal line is drawn at 
the sample mean. The center vertical lines drawn from the 
boxes extend to the minimum and the maximum. Expression 
of LMO4 mRNA was normalized to that of 18S rRNA.Molecular Cancer 2008, 7:93 http://www.molecular-cancer.com/content/7/1/93
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higher levels of LMO4 than did non-malignant IPMN or
normal ductal cells. By contrast, we could not detect any
differences in LMO4 expression among PanIN-1B, PanIN-
2 and normal ductal cells, or among IPMA, IPMB, and
normal ductal cells. Taken together, these data suggested
that LMO4 expression is up-regulated in pancreatic cancer
but not in low-grade intraductal precursors in both the
PanIN-IDC and IPMA-IPMC pathways.
This is the first report to use qRT-PCR for analyses of
LMO4 expression during pancreatic carcinogenesis. LMO4
is reported to have an oncogenic role in carcinogenesis
and in carcinoma progression in breast cancer and SCC
[18-21]. However, the human LMO4 gene is located on
chromosome 1p22.3 [35], which is a region deleted in
several human cancers, such as those of liver, skin, and
lung [36,37], and Setogawa et al reported that the tumor
suppressor LKB1 induces p21 expression in collaboration
with LMO4, suggesting that LMO4 may have a tumor sup-
pressor function [34]. In the present study, we found that
there was significant correlation between LMO4 and LKB1
in both primary cultured fibroblasts and microdissected
Correlation analyses between LKB1 and LMO4 in pancreatic carcinogenesis Figure 7
Correlation analyses between LKB1 and LMO4 in pancreatic carcinogenesis. a, Correlation between LKB1 and LMO4 
in primary cultured fibroblasts (spearman test, p = 0.037, top) and correlation between LKB1 and LMO4 in cultured cancer cell 
lines (spearman test, p = 0.39, bottom). b, Expression of LKB1 mRNA levels in microdissected normal ducts, PanIN-1B cells, 
and IDC cells (top). The bottom and the top edges of the box mark the lower bound and upper bound of the 95% Confidence 
Interval for the Mean, respectively. The center horizontal line is drawn at the sample mean. The center vertical lines drawn 
from the boxes extend to the minimum and the maximum. Correlation between LKB1 and LMO4 mRNA levels in non-malig-
nant cells (including normal ducts and PanIN-1B cells, spearman test, p = 0.042, middle), and correlation between LKB1 and 
LMO4 mRNA levels in IDC cells (spearman test, p = 0.453, bottom). Expression of LMO4 mRNA was normalized to that of 18S 
rRNA.
a bMolecular Cancer 2008, 7:93 http://www.molecular-cancer.com/content/7/1/93
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non-malignant cells, but there was not a significant corre-
lation between LMO4 and LKB1 in cancer cells. We also
found the downregulation of LKB1 mRNA in IDC cells,
consistent with LKB1's tumor suppressive function. Our
data suggest that alteration of the LKB1-LMO4 balance is
involved in pancreatic carcinogenesis, although the exact
function of LMO4 in pancreatic carcinogenesis remains
unknown. Taken together, there appears to be a conflict-
ing function of LMO4 in carcinogenesis as a tumor sup-
pressor or as an oncogene; it is reasonable that LMO4, a
transcription regulator, may have multiple functions in
individual cancers, like E2F1, an another transcription fac-
tor, that was reported both as an oncogene by stimulating
cell proliferation [38] and as a tumor suppressor by sign-
aling p53-dependent apoptosis [39].
Recently, Murphy et al [40] used immunohistochemical
staining and reported that a subset of patients with low
LMO4 expression-pancreatic cancers had poor outcomes.
In the present study, LMO4 mRNA was not overexpressed
in any of the 14 pancreatic cancer cell lines. However, all
IDC cells microdissected from cancer tissues showed rela-
tively high expression of LMO4 mRNA although the sam-
ple number was small. This might have been the result of
using of frozen sections with a histological diagnosis of
moderately or well-differentiated adenocarcinoma, which
can be microdissected easily. Patients with well-differenti-
ated adenocarcinoma usually have better prognosis [41];
thus the present data may be partially consistent with
Murphy's result demonstrating that high LMO4-pancre-
atic cancers are associated with a significant survival
advantage for patients with surgical resection.
Taken together, it remains unclear if LMO4 has an onco-
genic function or a tumor suppressive function in pancre-
atic carcinogenesis. To better clarify the functional roles of
LMO4 in pancreatic carcinogenesis, further examinations
such as inhibition experiments using RNAi technology are
needed.
In conclusion, the present results showed that LMO4 is
overexpressed in pancreatic cancer related to both the
PanIN-conventional IDC pathway and the IPMA-IPMC
pathway, but not at the early stages of pancreatic carcino-
genesis.
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